Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Is Topiramate Effective in Treating Dizziness in Patient's With Migraine-Associated Dizziness

This study has been withdrawn prior to enrollment.
(No subjects enrolled)
American Academy of Otolaryngology-Head and Neck Surgery Foundation
Information provided by:
University of California, San Francisco Identifier:
First received: August 7, 2008
Last updated: July 18, 2011
Last verified: July 2011

The purpose of this study is to determine whether topiramate effective in treating dizziness symptoms that are associated with migraine headaches.

Condition Intervention
Drug: topiramate
Drug: lactulose placebo pill

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Efficacy of Topiramate in Patients Wih Migraine-Associated Dizziness

Resource links provided by NLM:

Further study details as provided by University of California, San Francisco:

Primary Outcome Measures:
  • Change in mean 28-day monthly vertigo frequency from baseline. [ Time Frame: 4 weeks, 8 weeks ] [ Designated as safety issue: No ]
  • Change in Dizziness Handicap Inventory scores from baseline. [ Time Frame: 4 weeks, 8 weeks ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Change in an individual's perception of vertigo symptoms based on a 1 to 10 scale. [ Time Frame: 4 weeks, 8 weeks ] [ Designated as safety issue: No ]

Estimated Enrollment: 80
Study Start Date: November 2008
Estimated Primary Completion Date: August 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: topiramate
topiramate 50mg orally for 2 weeks, then 100mg orally for 6 weeks
Drug: topiramate
50mg orally for 2 weeks, then 100mg orally for 6 weeks
Other Name: Topamax
Placebo Comparator: 2
1 placebo pill orally for 2 weeks, then 2 placebo pills orally for 6 weeks
Drug: lactulose placebo pill
1 placebo pill orally for 2 weeks, then 2 placebo pills orally for 6 weeks
Other Name: placebo pill

Detailed Description:

Migraine is a common disorder, often associated with dizziness symptoms. In many cases, dizziness is one of the only manifestations of migraine headaches. Various classes of drugs have been advocated as treatment for migraine-associated dizziness, though none has been shown to be superior over the others.

Topiramate is a drug approved for migraine prophylaxis. This study is designed to assess if there are significant changes in dizziness frequency and severity in patients diagnosed with migraine-associated dizziness treated with topiramate. Demonstrating benefit of topiramate with a placebo-controlled study to alleviate symptoms of dizziness would serve to clarify effective treatment options for patients with migraine-associated dizziness.


Ages Eligible for Study:   18 Years to 65 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Clinical diagnosis of migraine-associated dizziness.

Exclusion Criteria:

  • Previous or current use of topiramate prior to study enrollment.
  • Need for continued use of the following medications for any medical reason during the study: ergots, anti-epileptics, beta-blockers, calcium channel blockers, monoamine oxidase inhibitors, high-dose magnesium, high-dose riboflavin, corticosteroids, local anesthetics, botulinum toxin, or herbal preparations.
  • History of nephrolithiasis.
  • Women whom are pregnant or breastfeeding.
  • Patients with known sensitivity to topiramate.
  • Patients with a history of glaucoma.
  • Patients with severe medical condition(s) that in the view of the investigator prohibits participation in the study.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00732108

United States, California
University of California, San Francisco
San Francisco, California, United States, 94143
Sponsors and Collaborators
University of California, San Francisco
American Academy of Otolaryngology-Head and Neck Surgery Foundation
Principal Investigator: Lawrence R Lustig, M.D. University of California, San Francisco
  More Information

No publications provided

Responsible Party: Lawrence R. Lustig, M.D., University of California, San Francisco Identifier: NCT00732108     History of Changes
Other Study ID Numbers: H48626-32352-01
Study First Received: August 7, 2008
Last Updated: July 18, 2011
Health Authority: United States: Institutional Review Board

Keywords provided by University of California, San Francisco:

Additional relevant MeSH terms:
Migraine Disorders
Brain Diseases
Central Nervous System Diseases
Ear Diseases
Headache Disorders
Headache Disorders, Primary
Labyrinth Diseases
Nervous System Diseases
Neurologic Manifestations
Otorhinolaryngologic Diseases
Sensation Disorders
Signs and Symptoms
Vestibular Diseases
Contraceptives, Oral
Anti-Obesity Agents
Central Nervous System Agents
Contraceptive Agents
Contraceptive Agents, Female
Neuroprotective Agents
Pharmacologic Actions
Physiological Effects of Drugs
Protective Agents
Reproductive Control Agents
Therapeutic Uses processed this record on February 25, 2015